Home Follow-Up Versus Clinic Visits After Heart Failure Hospital Stay
Compares digital follow-up at home with clinic visits for adults discharged after heart failure.
Plain-language title generated from the registry record
Registry title: Management of Patients With Heart Failure at Home After Hospital Discharge
Key facts
- Where
- Ålesund, Arendal, Drammen, Hamar, Levanger, Lørenskog, Moss, Oslo, Stavanger, Tønsberg, and Tromsø, NorwaySee the 11 sites
Where in Norway
- Ålesund HospitalÅlesund, NorwayTaking people
- Sørlandet SykehusArendal, NorwayTaking people
- Drammen Hospital, Vestre Viken HFDrammen, NorwayTaking people
- Innlandet sykehusHamar, NorwayTaking people
- Levanger sykehusLevanger, NorwayTaking people
- Akershus University HospitalLørenskog, NorwayTaking people
- Østfold HospitalMoss, NorwayTaking people
- Oslo University HospitalOslo, NorwayTaking people
- Stavanger University HospitalStavanger, NorwayTaking people
- Tønsberg SykehusTønsberg, NorwayTaking people
- Tromsø University HospitalTromsø, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Akershus
- Trial code
- NCT06576752
- Record updated
- 17 June 2026
- Original description
This study aims to assess whether patients with acute heart failure (HF) can achieve the same level of HF-therapies by digital follow-up at home as compared to hospital visits according to the STRONG-HF strategy. Patients admitted to hospital with acute HF will be enrolled and randomized to either follow-up at the hospital out-patient clinic or digital follow-up at home.Read full original descriptionShow less
Contemporary Post-Discharge Management in Heart Failure at Home
This study aims to assess whether patients with acute heart failure (HF) can achieve the same level of HF-therapies by digital follow-up at home as compared to hospital visits according to the STRONG-HF strategy. Patients admitted to hospital with acute HF will be enrolled and randomized to either follow-up at the hospital out-patient clinic or digital follow-up at home.
Inclusion: Hospital admission within the 72 hours prior to screening for acute HF; NT-proBNP ≥ 1,000 pg/mL measured during the hospitalization; Systolic blood pressure ≥ 100 mmHg and of heart rate ≥ 60 bpm within 24 hours before randomization; Serum potassium ≤ 5.0 mEq/L (mmol/L); ≤ ½ the optimal dose of ACEi/ARB/ARNi or beta-blocker or MRA; Written informed consent to participate in the study.
Exclusion: Prior (defined as less than 30 days from screening) or current enrollment in a HF intervention or participation in an investigational drug or device study within the 30 days prior to screening; Index event (admission for acute HF) triggered primarily by a completely reversable etiology so that it is unlikely the patient will be classified with chronic HF after discharge, such as Takotsubo syndrome (stress cardiomyopathy). In the setting of acute coronary syndrome or tachycardia, this should be managed before considering the presence of HF. This does not apply to patients with chronic HF prior to the index event; Severe non-adherence to medications; Psychiatric or neurological disorder, cirrhosis, or active malignancy leading to a life expectancy less than 6 months; History of heart transplant or on a transplant list, or using or planned to be implanted with a ventricular assist device; Uncorrected thyroid disease, active myocarditis, or known amyloid or hypertrophic obstructive cardiomyopathy; Inability to comply with all study requirements, due to major co-morbidities, social or financial issues, or a history of noncompliance with medical regimens, that might compromise the patients ability to understand and/or comply with the protocol instructions or follow-up procedures; Renal disease or estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73m2 at screening or history of dialysis; Age below 18 or above 85 years; Clearly documented intolerance to high doses of beta-blockers; Clearly documented intolerance to high doses of renin-angiotensin system (RAS) blockers (both ACEi and ARB); Low digital competency classified as inability to handle a smartphone or tablet; Language barriers requiring the need for an external interpreter; Pregnant or nursing (lactating) women.